BRISTOL, Tenn. and PALATINE, Ill., May 27, 2008 (PRIME NEWSWIRE) -- King Pharmaceuticals, Inc. (NYSE:KG) and Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced that King has exercised its option to license a third immediate-release opioid analgesic product utilizing Acura's proprietary AVERSION(r) Technology.
